A Long-Acting Prostacyclin Agonist with Thromboxane Inhibitory Activity for Pulmonary Hypertension
http://www.100md.com
《美国呼吸和危急护理医学》
Department of Regenerative Medicine and Tissue Engineering and Department of Biochemistry, National Cardiovascular Center Research Institute
Department of Internal Medicine, National Cardiovascular Center
Ono Pharmaceutical Co., Ltd., Research Headquarters, Osaka
Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
ABSTRACT
Rationale: The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity.
Objectives: We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats.
Methods: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk.
Measurements and Main Results: There was significant development of pulmonary hypertension 3 wk after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half-life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 h. A single administration of ONO-1301 increased plasma cyclic adenosine 3', 5'-monophosphate level, which lasted at least up to 8 h. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B2, a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80 vs. 30% in 6-wk survival).
Conclusions: Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3', 5'-monophosphate and inhibition of thromboxane synthase.
Key Words: cAMP monocrotaline hemodynamics vascular remodeling
Pulmonary arterial hypertension is a rare but life-threatening disease (1, 2). The pathogenesis includes pulmonary vasoconstriction, endothelial cell proliferation, smooth muscle cell proliferation, and in situ thrombosis (3, 4). Prostacyclin, a metabolite of arachidonic acid, has vasoprotective effects, including vasodilation, antiplatelet aggregation, and inhibition of smooth muscle cell proliferation (5–8). Thus, continuous intravenous infusion of prostacyclin (epoprostenol) has become recognized as a therapeutic breakthrough for pulmonary arterial hypertension (9–16). The dramatic success of long-term intravenous prostacyclin has led to the development of prostacyclin analogs (oral beraprost, aerosolized iloprost, and subcutaneous treprostinil; Figure 1) (17–20). Nevertheless, treatment with prostacyclin or its analogs has some problems in the clinical setting. Their duration of acting is so short that they need to be continuously infused or frequently administered (9–20). In addition, these compounds failed to inhibit thromboxane synthesis during treatment (21).
We developed a new type of prostacyclin agonist, ONO-1301, which has long-lasting prostacyclin activity and thromboxane synthase inhibitory activity. Prostacyclin and its analogs are unstable because 15-hydroxyprostaglandin dehydrogenase metabolizes their prostanoid structures, including a five-membered ring and allylic alcohol. In contrast, ONO-1301 is chemically and biologically stable because of the absence of prostanoid structures. Interestingly, ONO-1301 has thromboxane synthase inhibitory activity because of the presence of a 3-pyridine radical. It has been reported that augmented release of thromboxane A2, which is both a potent pulmonary vasoconstrictor and a procoagulant (22), occurs in patients with pulmonary hypertension (23, 24). The imbalance of thromboxane and prostacyclin is considered to contribute to the development of pulmonary arterial hypertension. These findings raise the possibility that administration of ONO-1301 may have beneficial effects on pulmonary hemodynamics.
Thus, the purposes of this study were (1) to investigate whether a single subcutaneous administration of ONO-1301 has long-lasting prostacyclin activity in rats, (2) to investigate whether subcutaneous administration of ONO-1301 inhibits thromboxane synthesis in monocrotaline (MCT)-induced pulmonary hypertension in rats, (3) to examine whether intermittent subcutaneous ONO-1301 improves pulmonary hemodynamics and survival in MCT rats, and (4) to elucidate the underlying mechanisms responsible for the beneficial effects of this compound.
METHODS
Animals
We used 95 male Wistar rats weighing 100 to 120 g. The rats were randomly given a subcutaneous injection of either 60 mg/kg MCT (MCT rats) or 0.9% saline (vehicle) and assigned to receive repeated subcutaneous injection of ONO-1301 (Ono Pharmaceutical Co., Ltd., Osaka, Japan) or vehicle. This protocol resulted in the creation of three groups: sham rats given vehicle (n = 10), MCT rats given vehicle (n = 10), and MCT rats treated with ONO-1301 (n = 13). In addition, 20 rats were studied to evaluate the effect of ONO-1301 on survival in MCT rats. Furthermore, 42 rats were studied to evaluate the effect of ONO-1301 on plasma cAMP level (n = 12) and 11-dehydro-thromboxane B2 (TXB2) level (n = 30).
In Vivo Experimental Protocol
After rats were anesthetized by intraperitoneal injection of pentobarbital (30 mg/kg), they were given a subcutaneous injection of either 60 mg/kg MCT or vehicle. Then, ONO-1301 (20 mg/kg/d) or vehicle was injected subcutaneously twice per day for 3 wk after MCT injection. Animals were maintained on standard rat chow. Hemodynamic studies were performed on Day 22. A polyethylene catheter (PE-50) was inserted into the right carotid artery to measure heart rate and mean arterial pressure. A polyethylene catheter (PE-50) was inserted through the right jugular vein into the right ventricle (RV) for measurement of RV pressure. Finally, cardiac arrest was induced by injection of 2 mmol/L potassium chloride through the catheter. The ventricles and lungs were excised, dissected free, and weighed. The ratio of RV weight to body weight (RV/BW), the ratio of left ventricular plus septal weight to body weight (LV + S/BW), and the ratio of RV weight to left ventricular plus septal weight (RV/LV + S) were calculated as indexes of ventricular hypertrophy, as reported previously (25). All protocols were performed in accordance with guidelines of the Animal Care Ethics Committee of the National Cardiovascular Center Research Institute.
Morphometric Analysis of Pulmonary Arteries
Paraffin sections 4-μm thick were obtained from the middle region of the right lung and stained with elastic van Gieson for examination by light microscopy. The external diameter and medial wall thickness of the pulmonary arteries were measured in 20 muscular arteries (ranging in size from 25 to 100 μm in external diameter) by two investigators who were blinded to treatment allocation. For each artery, the medial wall thickness was expressed as follows: % wall thickness = ([medial thickness x 2]/external diameter) x 100, as reported previously (26).
Assay for Plasma ONO-1301 Concentration
To estimate the half-life of ONO-1301, we measured plasma ONO-1301 concentration in rats after a subcutaneous injection (n = 4). Blood was drawn at 0.25, 0.5, 1, 2, 4, 8, and 24 h after a single subcutaneous administration of ONO-1301 (10 mg/kg). Plasma ONO-1301 concentration was measured by liquid chromatography tandem mass spectrometry assay.
Assay for Plasma cAMP Level
To investigate whether a single subcutaneous administration of ONO-1301 has long-lasting prostacyclin activity in rats, we measured plasma cAMP levels after ONO-1301 injection. Twelve rats were assigned to receive a single subcutaneous injection of ONO-1301 (10 mg/kg) or vehicle (n = 6 each). Blood was drawn from the right carotid artery at baseline and 1, 2, 4, 6, and 8 h after ONO-1301 injection. Blood was immediately transferred into a chilled glass tube containing disodium ethylenediaminetetraacetic acid (1 mg/ml) and aprotinin (500 U/ml) and centrifuged immediately. Plasma cAMP levels was measured with a radioimmunoassay kit (cAMP assay kit; Yamasa Shoyu, Chiba, Japan), as reported previously (27).
Assay for Plasma 11-dehydro-TXB2 Level
To investigate the acute effect of ONO-1301 or prostacyclin (epoprostenol) on thromboxane synthesis in MCT rats, we measured plasma 11-dehydro-TXB2, a metabolite of thromboxane A2, after administration of ONO-1301 (10 mg/kg), epoprostenol, or vehicle (n = 5 each). Epoprostenol was infused via a polyethylene catheter (PE-50) inserted into the right jugular vein. Infusion of epoprostenol was begun at 10 ng/kg/min, increased gradually to 150 ng/kg/min over 30 min, escalated to 300 ng/kg/min over the next 30 min, and held at this dose for 1 h, as reported previously (21, 28, 29).
To investigate the chronic effect of ONO-1301 on thromboxane synthesis in MCT rats, we measured plasma 11-dehydro-TXB2 after repeated subcutaneous injection of ONO-1301 (20 mg/kg/d) or vehicle twice per day for 3 wk (n = 5 each). Blood was drawn from the right carotid artery and plasma 11-dehydro-TXB2 level was measured with an enzyme immunoassay kit (11-dehydro-TXB2 assay kit; Cayman Chemical Co., Ann Arbor, MI), as reported previously (30).
Survival Analysis
To evaluate the effect of intermittent subcutaneous administration of ONO-1301 on survival in MCT rats, 20 rats received repeated injection of ONO-1301 or vehicle twice per day (n = 10 each). Survival was estimated from the date of MCT injection to the death of the rat or 6 wk after injection.
Statistical Analysis
All data were expressed as mean ± SEM. Comparisons of parameters among the three groups were made by one-way analysis of variance, followed by Newman-Keuls' test. Comparisons of the time course of parameters between the two groups were made by two-way analysis of variance for repeated measures, followed by Newman-Keuls' test. Survival curves were derived by the Kaplan-Meier method and compared by log-rank test. A value of p < 0.05 was considered statistically significant.
RESULTS
Effects of ONO-1301 on Pulmonary Hemodynamics and Vascular Remodeling
RV systolic pressure was significantly increased 3 wk after MCT injection (Figure 2A). However, the increase was significantly attenuated by subcutaneous administration of ONO-1301 (10 mg/kg twice per day). Similarly, the increases in RV/BW and RV/LV + S in MCT rats were significantly attenuated by treatment with ONO-1301 (Figures 2B and 2C). There were no significant differences in heart rate or mean arterial pressure among the three groups (Table 1).
Representative photomicrographs showed that hypertrophy of the pulmonary vessel wall after MCT injection was attenuated in MCT rats treated with ONO-1301 compared with those given vehicle (Figure 3A). Quantitative analysis demonstrated a significant increase in percent wall thickness after MCT injection, but this change was ameliorated by ONO-1301 (Figure 3B).
Long-Lasting Activity of ONO-1301
We measured plasma ONO-1301 concentrations after a single subcutaneous administration of ONO-1301. The increase in plasma ONO-1301 concentration reached a peak at 4 h, and the half-life of plasma ONO-1301 concentration was approximately 5.6 h (Figure 4). In addition, a single subcutaneous administration of ONO-1301 significantly increased plasma cAMP level in rats (Figure 5). The increase in plasma cAMP level reached a peak at 6 h and lasted at least up to 8 h after ONO-1301 injection. These results suggest that subcutaneous administration of ONO-1301 has long-lasting activity in rats.
Inhibitory Effect of ONO-1301 on Thromboxane Synthase
Although administration of prostacyclin (epoprostenol) markedly increased plasma 11-dehydro-TXB2 level in MCT rats with established pulmonary hypertension, ONO-1301 did not significantly increase plasma 11-dehydro-TXB2 level, even after bolus injection (Figure 6A). Plasma 11-dehydro-TXB2 level was markedly elevated 3 wk after MCT injection (Figure 6B). However, 3-wk treatment with ONO-1301 significantly attenuated the increase in plasma 11-dehydro-TXB2 level in MCT rats.
Survival Analysis
Kaplan-Meier survival curves demonstrated that MCT rats treated with ONO-1301 had a significantly higher survival rate than MCT rats given vehicle (80 vs. 30% in 6-wk survival; Figure 7).
DISCUSSION
In the present study, we demonstrated that (1) a novel prostacyclin agonist (ONO-1301) ameliorated the development of MCT-induced pulmonary hypertension and improved survival in MCT rats; (2) ONO-1301 had a long half-life of approximately 5.6 h, and a single administration of ONO-1301 caused a long-lasting increase in plasma cAMP level; and (3) ONO-1301 attenuated the increase in plasma 11-dehydro-TXB2 level in MCT rats.
Conventional prostacyclin and its analogs need continuous infusion or frequent administration because of their short duration of acting. Epoprostenol has a very short half-life (< 6 min), iloprost has a serum half-life of 20 to 25 min, and the elimination half-life of beraprost is 35 to 40 min after oral administration (31). Treprostinil sodium, a stable prostacyclin analog, has been reported to have a half-life of 4.6 h after cessation of continuous subcutaneous infusion (32). With regard to cAMP, a second messenger of prostacyclin and its analogs, it has been reported that plasma cAMP levels remained increased at 4 h and normalized at 6 h after inhalation of iloprost (33), and that plasma cAMP levels reached a peak at 30 min and subsequently returned to baseline levels at 2 h after administration of oral beraprost (27). In our results, the half-life of plasma ONO-1301 concentration was approximately 5.6 h, and a single subcutaneous administration of ONO-1301 increased plasma cAMP level at least up to 8 h. Because the method for administration was different between ONO-1301 and conventional prostacyclin analogs (compare a subcutaneous single shot of ONO-1301, continuous intravenous infusion of epoprostenol, continuous subcutaneous infusion of treprostinil, inhalation of iloprost, and oral administration of beraprost), it is difficult to directly compare the lasting effects of prostacyclin activity of ONO-1301 with that of conventional prostacyclin analogs. Nevertheless, the long half-life of ONO-1301 and long-lasting increases in plasma cAMP levels indicate that ONO-1301 exhibits chemical and biologic stability comparable to that of conventional prostacyclin and its analogs. ONO-1301 does not contain prostanoid structures such as a five-membered ring and allylic alcohol, which are subject to metabolism by 15-hydroxyprostaglandin dehydrogenase. These may be the reason for the long-lasting activity of ONO-1301. The present study also demonstrated that repeated administration of ONO-1301 twice per day markedly attenuated the development of MCT-induced pulmonary hypertension, as indicated by significant decreases in RV systolic pressure and RV weight. Thus, intermittent subcutaneous administration of ONO-1301 may be sufficient for the treatment of pulmonary hypertension.
Thromboxane, produced by endothelial cells and platelets, has a potent vasoconstrictor effect, smooth muscle mitogenic property, and platelet aggregation effect (22). Earlier studies have demonstrated impaired prostacyclin synthesis and increased thromboxane production in patients with pulmonary arterial hypertension, suggesting that imbalance of the release of thromboxane and prostacyclin plays an important role in the development of pulmonary hypertension (23, 24). Furthermore, thromboxane-receptor density is increased in the RV of patients with pulmonary hypertension (34). Rich and colleagues have shown that inhibition of thromboxane synthase modestly improves pulmonary hemodynamics in patients with pulmonary arterial hypertension (35). ONO-1301 has a 3-pyridine radical, which is known to inhibit thromboxane synthase through interaction with carboxylic acid via a hydrogen bond. In the present study, plasma 11-dehydro-TXB2 level was markedly elevated in MCT rats. However, treatment with ONO-1301 greatly diminished its level. Furthermore, in the acute phase, plasma 11-dehydro-TXB2 level in MCT rats did not significantly increase after administration of ONO-1301, although the plasma level markedly increased after epoprostenol infusion, which is consistent with the earlier study of Cuiper and colleagues (21). Therefore, it is possible that ONO-1301 attenuates MCT-induced pulmonary hypertension partly via improvement of prostacyclin/thromboxane imbalance.
In the present study, ONO-1301 also attenuated the increase in medial wall thickness of peripheral pulmonary arteries. Activation of prostacyclin receptors has been shown to suppress the growth of vascular smooth muscle cells through a cAMP-dependent pathway. Thus, ONO-1301 may attenuate the development of pulmonary vascular remodeling at least in part via a cAMP-dependent pathway. Importantly, repeated administration of ONO-1301 improved survival in MCT rats compared with vehicle administration. The increased survival rate in MCT rats is considered to be associated with the amelioration of pulmonary hypertension. Thus, intermittent subcutaneous administration of ONO-1301 may be an alternative approach for severe pulmonary hypertension refractory to conventional therapy.
In conclusion, subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated MCT-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cAMP and inhibition of thromboxane synthase. Thus, administration of this compound may be a promising therapeutic strategy for the treatment of pulmonary arterial hypertension.
FOOTNOTES
Supported by grants from Ono Pharmaceutical Co., Ltd.
Originally Published in Press as DOI: 10.1164/rccm.200501-102OC on September 28, 2005
Conflict of Interest Statement: None of the authors have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
REFERENCES
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216–223.
McLaughlin VV, Rich S. Pulmonary hypertension. Curr Probl Cardiol 2004;29:575–634.
Rich S. Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest 1998;114:237S–241S.
Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "work in progress." Circulation 2000;102:2781–2791.
Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663–665.
Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979;300:1142–1147.
Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 2000;102:2005–2012.
Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184–1187.
Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046–1047.
Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485–491.
Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, Wallwork J. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993;70:366–370.
Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409–415.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–301.
McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273–277.
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–788.
Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365.
Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Miyatake K, Kunieda T. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188–1192.
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–329.
Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med 2002;165:800–804.
Cuiper LL, Patricia VP, Christman BW. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. J Appl Physiol 1996;80:191–197.
Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159–165.
Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70–75.
Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth SG. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993;88:2117–2122.
Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, Yutani C, Yamagishi M, Kimura H, Kangawa K. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;170:1204–1211.
Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003;108:889–895.
Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, Kangawa K, Kimura H. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34–38.
Sun FF, Taylor BM. Metabolism of prostacyclin in rat. Biochemistry 1978;17:4096–4101.
Taylor BM, Sun FF. Tissue distribution and biliary excretion of prostacyclin metabolites in the rat. J Pharmacol Exp Ther 1980;214:24–30.
Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A 1986;83:5861–5865.
Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S–61S.
Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44:209–214.
Beghetti M, Reber G, de MP, Vadas L, Chiappe A, Spahr-Schopfer I, Rimensberger PC. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002;19:518–524.
Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001;134:1385–1392.
Rich S, Hart K, Kieras K, Brundage BH. Thromboxane synthetase inhibition in primary pulmonary hypertension. Chest 1987;91:356–360.(Masaharu Kataoka, Noritoshi Nagaya, Toru)
Department of Internal Medicine, National Cardiovascular Center
Ono Pharmaceutical Co., Ltd., Research Headquarters, Osaka
Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
ABSTRACT
Rationale: The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity.
Objectives: We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats.
Methods: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk.
Measurements and Main Results: There was significant development of pulmonary hypertension 3 wk after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half-life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 h. A single administration of ONO-1301 increased plasma cyclic adenosine 3', 5'-monophosphate level, which lasted at least up to 8 h. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B2, a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80 vs. 30% in 6-wk survival).
Conclusions: Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3', 5'-monophosphate and inhibition of thromboxane synthase.
Key Words: cAMP monocrotaline hemodynamics vascular remodeling
Pulmonary arterial hypertension is a rare but life-threatening disease (1, 2). The pathogenesis includes pulmonary vasoconstriction, endothelial cell proliferation, smooth muscle cell proliferation, and in situ thrombosis (3, 4). Prostacyclin, a metabolite of arachidonic acid, has vasoprotective effects, including vasodilation, antiplatelet aggregation, and inhibition of smooth muscle cell proliferation (5–8). Thus, continuous intravenous infusion of prostacyclin (epoprostenol) has become recognized as a therapeutic breakthrough for pulmonary arterial hypertension (9–16). The dramatic success of long-term intravenous prostacyclin has led to the development of prostacyclin analogs (oral beraprost, aerosolized iloprost, and subcutaneous treprostinil; Figure 1) (17–20). Nevertheless, treatment with prostacyclin or its analogs has some problems in the clinical setting. Their duration of acting is so short that they need to be continuously infused or frequently administered (9–20). In addition, these compounds failed to inhibit thromboxane synthesis during treatment (21).
We developed a new type of prostacyclin agonist, ONO-1301, which has long-lasting prostacyclin activity and thromboxane synthase inhibitory activity. Prostacyclin and its analogs are unstable because 15-hydroxyprostaglandin dehydrogenase metabolizes their prostanoid structures, including a five-membered ring and allylic alcohol. In contrast, ONO-1301 is chemically and biologically stable because of the absence of prostanoid structures. Interestingly, ONO-1301 has thromboxane synthase inhibitory activity because of the presence of a 3-pyridine radical. It has been reported that augmented release of thromboxane A2, which is both a potent pulmonary vasoconstrictor and a procoagulant (22), occurs in patients with pulmonary hypertension (23, 24). The imbalance of thromboxane and prostacyclin is considered to contribute to the development of pulmonary arterial hypertension. These findings raise the possibility that administration of ONO-1301 may have beneficial effects on pulmonary hemodynamics.
Thus, the purposes of this study were (1) to investigate whether a single subcutaneous administration of ONO-1301 has long-lasting prostacyclin activity in rats, (2) to investigate whether subcutaneous administration of ONO-1301 inhibits thromboxane synthesis in monocrotaline (MCT)-induced pulmonary hypertension in rats, (3) to examine whether intermittent subcutaneous ONO-1301 improves pulmonary hemodynamics and survival in MCT rats, and (4) to elucidate the underlying mechanisms responsible for the beneficial effects of this compound.
METHODS
Animals
We used 95 male Wistar rats weighing 100 to 120 g. The rats were randomly given a subcutaneous injection of either 60 mg/kg MCT (MCT rats) or 0.9% saline (vehicle) and assigned to receive repeated subcutaneous injection of ONO-1301 (Ono Pharmaceutical Co., Ltd., Osaka, Japan) or vehicle. This protocol resulted in the creation of three groups: sham rats given vehicle (n = 10), MCT rats given vehicle (n = 10), and MCT rats treated with ONO-1301 (n = 13). In addition, 20 rats were studied to evaluate the effect of ONO-1301 on survival in MCT rats. Furthermore, 42 rats were studied to evaluate the effect of ONO-1301 on plasma cAMP level (n = 12) and 11-dehydro-thromboxane B2 (TXB2) level (n = 30).
In Vivo Experimental Protocol
After rats were anesthetized by intraperitoneal injection of pentobarbital (30 mg/kg), they were given a subcutaneous injection of either 60 mg/kg MCT or vehicle. Then, ONO-1301 (20 mg/kg/d) or vehicle was injected subcutaneously twice per day for 3 wk after MCT injection. Animals were maintained on standard rat chow. Hemodynamic studies were performed on Day 22. A polyethylene catheter (PE-50) was inserted into the right carotid artery to measure heart rate and mean arterial pressure. A polyethylene catheter (PE-50) was inserted through the right jugular vein into the right ventricle (RV) for measurement of RV pressure. Finally, cardiac arrest was induced by injection of 2 mmol/L potassium chloride through the catheter. The ventricles and lungs were excised, dissected free, and weighed. The ratio of RV weight to body weight (RV/BW), the ratio of left ventricular plus septal weight to body weight (LV + S/BW), and the ratio of RV weight to left ventricular plus septal weight (RV/LV + S) were calculated as indexes of ventricular hypertrophy, as reported previously (25). All protocols were performed in accordance with guidelines of the Animal Care Ethics Committee of the National Cardiovascular Center Research Institute.
Morphometric Analysis of Pulmonary Arteries
Paraffin sections 4-μm thick were obtained from the middle region of the right lung and stained with elastic van Gieson for examination by light microscopy. The external diameter and medial wall thickness of the pulmonary arteries were measured in 20 muscular arteries (ranging in size from 25 to 100 μm in external diameter) by two investigators who were blinded to treatment allocation. For each artery, the medial wall thickness was expressed as follows: % wall thickness = ([medial thickness x 2]/external diameter) x 100, as reported previously (26).
Assay for Plasma ONO-1301 Concentration
To estimate the half-life of ONO-1301, we measured plasma ONO-1301 concentration in rats after a subcutaneous injection (n = 4). Blood was drawn at 0.25, 0.5, 1, 2, 4, 8, and 24 h after a single subcutaneous administration of ONO-1301 (10 mg/kg). Plasma ONO-1301 concentration was measured by liquid chromatography tandem mass spectrometry assay.
Assay for Plasma cAMP Level
To investigate whether a single subcutaneous administration of ONO-1301 has long-lasting prostacyclin activity in rats, we measured plasma cAMP levels after ONO-1301 injection. Twelve rats were assigned to receive a single subcutaneous injection of ONO-1301 (10 mg/kg) or vehicle (n = 6 each). Blood was drawn from the right carotid artery at baseline and 1, 2, 4, 6, and 8 h after ONO-1301 injection. Blood was immediately transferred into a chilled glass tube containing disodium ethylenediaminetetraacetic acid (1 mg/ml) and aprotinin (500 U/ml) and centrifuged immediately. Plasma cAMP levels was measured with a radioimmunoassay kit (cAMP assay kit; Yamasa Shoyu, Chiba, Japan), as reported previously (27).
Assay for Plasma 11-dehydro-TXB2 Level
To investigate the acute effect of ONO-1301 or prostacyclin (epoprostenol) on thromboxane synthesis in MCT rats, we measured plasma 11-dehydro-TXB2, a metabolite of thromboxane A2, after administration of ONO-1301 (10 mg/kg), epoprostenol, or vehicle (n = 5 each). Epoprostenol was infused via a polyethylene catheter (PE-50) inserted into the right jugular vein. Infusion of epoprostenol was begun at 10 ng/kg/min, increased gradually to 150 ng/kg/min over 30 min, escalated to 300 ng/kg/min over the next 30 min, and held at this dose for 1 h, as reported previously (21, 28, 29).
To investigate the chronic effect of ONO-1301 on thromboxane synthesis in MCT rats, we measured plasma 11-dehydro-TXB2 after repeated subcutaneous injection of ONO-1301 (20 mg/kg/d) or vehicle twice per day for 3 wk (n = 5 each). Blood was drawn from the right carotid artery and plasma 11-dehydro-TXB2 level was measured with an enzyme immunoassay kit (11-dehydro-TXB2 assay kit; Cayman Chemical Co., Ann Arbor, MI), as reported previously (30).
Survival Analysis
To evaluate the effect of intermittent subcutaneous administration of ONO-1301 on survival in MCT rats, 20 rats received repeated injection of ONO-1301 or vehicle twice per day (n = 10 each). Survival was estimated from the date of MCT injection to the death of the rat or 6 wk after injection.
Statistical Analysis
All data were expressed as mean ± SEM. Comparisons of parameters among the three groups were made by one-way analysis of variance, followed by Newman-Keuls' test. Comparisons of the time course of parameters between the two groups were made by two-way analysis of variance for repeated measures, followed by Newman-Keuls' test. Survival curves were derived by the Kaplan-Meier method and compared by log-rank test. A value of p < 0.05 was considered statistically significant.
RESULTS
Effects of ONO-1301 on Pulmonary Hemodynamics and Vascular Remodeling
RV systolic pressure was significantly increased 3 wk after MCT injection (Figure 2A). However, the increase was significantly attenuated by subcutaneous administration of ONO-1301 (10 mg/kg twice per day). Similarly, the increases in RV/BW and RV/LV + S in MCT rats were significantly attenuated by treatment with ONO-1301 (Figures 2B and 2C). There were no significant differences in heart rate or mean arterial pressure among the three groups (Table 1).
Representative photomicrographs showed that hypertrophy of the pulmonary vessel wall after MCT injection was attenuated in MCT rats treated with ONO-1301 compared with those given vehicle (Figure 3A). Quantitative analysis demonstrated a significant increase in percent wall thickness after MCT injection, but this change was ameliorated by ONO-1301 (Figure 3B).
Long-Lasting Activity of ONO-1301
We measured plasma ONO-1301 concentrations after a single subcutaneous administration of ONO-1301. The increase in plasma ONO-1301 concentration reached a peak at 4 h, and the half-life of plasma ONO-1301 concentration was approximately 5.6 h (Figure 4). In addition, a single subcutaneous administration of ONO-1301 significantly increased plasma cAMP level in rats (Figure 5). The increase in plasma cAMP level reached a peak at 6 h and lasted at least up to 8 h after ONO-1301 injection. These results suggest that subcutaneous administration of ONO-1301 has long-lasting activity in rats.
Inhibitory Effect of ONO-1301 on Thromboxane Synthase
Although administration of prostacyclin (epoprostenol) markedly increased plasma 11-dehydro-TXB2 level in MCT rats with established pulmonary hypertension, ONO-1301 did not significantly increase plasma 11-dehydro-TXB2 level, even after bolus injection (Figure 6A). Plasma 11-dehydro-TXB2 level was markedly elevated 3 wk after MCT injection (Figure 6B). However, 3-wk treatment with ONO-1301 significantly attenuated the increase in plasma 11-dehydro-TXB2 level in MCT rats.
Survival Analysis
Kaplan-Meier survival curves demonstrated that MCT rats treated with ONO-1301 had a significantly higher survival rate than MCT rats given vehicle (80 vs. 30% in 6-wk survival; Figure 7).
DISCUSSION
In the present study, we demonstrated that (1) a novel prostacyclin agonist (ONO-1301) ameliorated the development of MCT-induced pulmonary hypertension and improved survival in MCT rats; (2) ONO-1301 had a long half-life of approximately 5.6 h, and a single administration of ONO-1301 caused a long-lasting increase in plasma cAMP level; and (3) ONO-1301 attenuated the increase in plasma 11-dehydro-TXB2 level in MCT rats.
Conventional prostacyclin and its analogs need continuous infusion or frequent administration because of their short duration of acting. Epoprostenol has a very short half-life (< 6 min), iloprost has a serum half-life of 20 to 25 min, and the elimination half-life of beraprost is 35 to 40 min after oral administration (31). Treprostinil sodium, a stable prostacyclin analog, has been reported to have a half-life of 4.6 h after cessation of continuous subcutaneous infusion (32). With regard to cAMP, a second messenger of prostacyclin and its analogs, it has been reported that plasma cAMP levels remained increased at 4 h and normalized at 6 h after inhalation of iloprost (33), and that plasma cAMP levels reached a peak at 30 min and subsequently returned to baseline levels at 2 h after administration of oral beraprost (27). In our results, the half-life of plasma ONO-1301 concentration was approximately 5.6 h, and a single subcutaneous administration of ONO-1301 increased plasma cAMP level at least up to 8 h. Because the method for administration was different between ONO-1301 and conventional prostacyclin analogs (compare a subcutaneous single shot of ONO-1301, continuous intravenous infusion of epoprostenol, continuous subcutaneous infusion of treprostinil, inhalation of iloprost, and oral administration of beraprost), it is difficult to directly compare the lasting effects of prostacyclin activity of ONO-1301 with that of conventional prostacyclin analogs. Nevertheless, the long half-life of ONO-1301 and long-lasting increases in plasma cAMP levels indicate that ONO-1301 exhibits chemical and biologic stability comparable to that of conventional prostacyclin and its analogs. ONO-1301 does not contain prostanoid structures such as a five-membered ring and allylic alcohol, which are subject to metabolism by 15-hydroxyprostaglandin dehydrogenase. These may be the reason for the long-lasting activity of ONO-1301. The present study also demonstrated that repeated administration of ONO-1301 twice per day markedly attenuated the development of MCT-induced pulmonary hypertension, as indicated by significant decreases in RV systolic pressure and RV weight. Thus, intermittent subcutaneous administration of ONO-1301 may be sufficient for the treatment of pulmonary hypertension.
Thromboxane, produced by endothelial cells and platelets, has a potent vasoconstrictor effect, smooth muscle mitogenic property, and platelet aggregation effect (22). Earlier studies have demonstrated impaired prostacyclin synthesis and increased thromboxane production in patients with pulmonary arterial hypertension, suggesting that imbalance of the release of thromboxane and prostacyclin plays an important role in the development of pulmonary hypertension (23, 24). Furthermore, thromboxane-receptor density is increased in the RV of patients with pulmonary hypertension (34). Rich and colleagues have shown that inhibition of thromboxane synthase modestly improves pulmonary hemodynamics in patients with pulmonary arterial hypertension (35). ONO-1301 has a 3-pyridine radical, which is known to inhibit thromboxane synthase through interaction with carboxylic acid via a hydrogen bond. In the present study, plasma 11-dehydro-TXB2 level was markedly elevated in MCT rats. However, treatment with ONO-1301 greatly diminished its level. Furthermore, in the acute phase, plasma 11-dehydro-TXB2 level in MCT rats did not significantly increase after administration of ONO-1301, although the plasma level markedly increased after epoprostenol infusion, which is consistent with the earlier study of Cuiper and colleagues (21). Therefore, it is possible that ONO-1301 attenuates MCT-induced pulmonary hypertension partly via improvement of prostacyclin/thromboxane imbalance.
In the present study, ONO-1301 also attenuated the increase in medial wall thickness of peripheral pulmonary arteries. Activation of prostacyclin receptors has been shown to suppress the growth of vascular smooth muscle cells through a cAMP-dependent pathway. Thus, ONO-1301 may attenuate the development of pulmonary vascular remodeling at least in part via a cAMP-dependent pathway. Importantly, repeated administration of ONO-1301 improved survival in MCT rats compared with vehicle administration. The increased survival rate in MCT rats is considered to be associated with the amelioration of pulmonary hypertension. Thus, intermittent subcutaneous administration of ONO-1301 may be an alternative approach for severe pulmonary hypertension refractory to conventional therapy.
In conclusion, subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated MCT-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cAMP and inhibition of thromboxane synthase. Thus, administration of this compound may be a promising therapeutic strategy for the treatment of pulmonary arterial hypertension.
FOOTNOTES
Supported by grants from Ono Pharmaceutical Co., Ltd.
Originally Published in Press as DOI: 10.1164/rccm.200501-102OC on September 28, 2005
Conflict of Interest Statement: None of the authors have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
REFERENCES
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216–223.
McLaughlin VV, Rich S. Pulmonary hypertension. Curr Probl Cardiol 2004;29:575–634.
Rich S. Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest 1998;114:237S–241S.
Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "work in progress." Circulation 2000;102:2781–2791.
Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663–665.
Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979;300:1142–1147.
Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 2000;102:2005–2012.
Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184–1187.
Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046–1047.
Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485–491.
Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, Wallwork J. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993;70:366–370.
Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409–415.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–301.
McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273–277.
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–788.
Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365.
Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Miyatake K, Kunieda T. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188–1192.
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–329.
Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med 2002;165:800–804.
Cuiper LL, Patricia VP, Christman BW. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. J Appl Physiol 1996;80:191–197.
Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159–165.
Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70–75.
Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth SG. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993;88:2117–2122.
Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, Yutani C, Yamagishi M, Kimura H, Kangawa K. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;170:1204–1211.
Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003;108:889–895.
Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, Kangawa K, Kimura H. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34–38.
Sun FF, Taylor BM. Metabolism of prostacyclin in rat. Biochemistry 1978;17:4096–4101.
Taylor BM, Sun FF. Tissue distribution and biliary excretion of prostacyclin metabolites in the rat. J Pharmacol Exp Ther 1980;214:24–30.
Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A 1986;83:5861–5865.
Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S–61S.
Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44:209–214.
Beghetti M, Reber G, de MP, Vadas L, Chiappe A, Spahr-Schopfer I, Rimensberger PC. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002;19:518–524.
Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001;134:1385–1392.
Rich S, Hart K, Kieras K, Brundage BH. Thromboxane synthetase inhibition in primary pulmonary hypertension. Chest 1987;91:356–360.(Masaharu Kataoka, Noritoshi Nagaya, Toru)